Gland Pharma Announces 48th AGM on Aug 25, 2026, Proposes ₹20 Final Dividend
Gland Pharma will hold its 48th AGM on August 25, 2026, via VC/OAVM. The company proposes a final dividend of ₹20 per equity share for FY26. Key agenda items include adopting financial statements and reappointing directors Mr. Wenjie Zhang and Ms. Wei Huang. E-voting is open from Aug 22-24, 2026.
The declaration of a final dividend and the reappointment of directors are standard corporate governance activities. The AGM is a procedural event, but the dividend payout is a material event for shareholders.
The announcement is a routine corporate event (AGM) and dividend declaration, with no significant positive or negative financial news or outlook provided.
Gland Pharma Limited has announced the details for its 48th Annual General Meeting (AGM), scheduled to be held on Tuesday, August 25, 2026, at 11:00 AM IST through Video Conference/Other Audio-Visual Means (OAVM). The company has also released its Annual Report for the financial year ended March 31, 2026.
The agenda for the AGM includes the adoption of audited standalone and consolidated financial statements for the fiscal year 2025-26. Furthermore, the Board of Directors has recommended a final dividend of ₹20 per equity share for the financial year ended March 31, 2026. The record date for determining the eligibility of shareholders for this dividend is Tuesday, August 11, 2026.
Additionally, the meeting will address the reappointment of Mr. Wenjie Zhang and Ms. Wei Huang as Directors, who are retiring by rotation and seeking reappointment. The e-voting period for the AGM will commence on Saturday, August 22, 2026, at 9:00 AM IST and conclude on Monday, August 24, 2026, at 5:00 PM IST. The cut-off date for e-voting is Tuesday, August 18, 2026.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.